Poltreg S.A. Logo

Poltreg S.A.

Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.

PTG | WAR

Overview

Corporate Details

ISIN(s):
PLPLTRG00012 (+2 more)
LEI:
259400XSAJTERJ42VZ86
Country:
Poland
Address:
GDAŃSK BOTANICZNA 20, 80-298 GDAŃSK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Poltreg S.A. is a clinical-stage biotechnology company pioneering the development of T-regulatory cell (Treg) therapies for autoimmune diseases. The company aims to establish Tregs as a new class of disease-modifying therapeutics. Its advanced pipeline features several clinical assets, with the lead candidate, PTG-007, being developed for Type-1 Diabetes and Multiple Sclerosis (MS). Poltreg is also advancing engineered cell therapies, including first-in-class CAR-Treg programs for MS and Amyotrophic Lateral Sclerosis (ALS). Leveraging its own manufacturing facilities and extensive experience, the company was the first to administer a Treg-based therapy to a patient.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 17:09
Audit Report / Information
Raport biegłego rewidenta z przeglądu sprawozdania finansowego
Polish 233.4 KB
2025-09-10 17:09
Management Discussion and Analysis
Sprawozdanie Zarządu z działalności za okres 6 miesięcy zakończony dnia 30 czer…
Polish 2.8 MB
2025-09-10 17:09
Interim Report
Sprawozdanie finansowe za okres 6 miesięcy zakończony dnia 30 czerwca 2025 roku
Polish 3.4 MB
2025-09-03 10:39
Regulatory News Service
Warunkowe przyznanie patentu przez Koreański Urząd Patentowy w projekcie terapi…
Polish 1.7 KB
2025-08-04 14:37
Legal Proceedings Report
Podanie pierwszemu pacjentowi terapii w ramach badania klinicznego fazy II w pr…
Polish 2.8 KB
2025-07-31 08:50
Legal Proceedings Report
Otrzymanie od FDA protokołu z podsumowaniem spotkania pre-IND - Content (PL)
Polish 2.0 KB
2025-07-29 14:05
Regulatory News Service
Otrzymanie Certyfikatu Dobrej Praktyki Wytwarzania od Głównego Inspektora Farma…
Polish 1005 bytes
2025-06-23 15:30
Regulatory News Service
Warunkowe przyznanie europejskiego patentu dotyczącego metody ekspansji ex vivo…
Polish 884 bytes
2025-06-13 15:56
Foreign Filer Report
Rejestracja spółki zależnej Immuthera w USA - Content (PL)
Polish 784 bytes
2025-05-21 12:30
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Zgromadze…
Polish 2.3 KB
2025-05-20 22:12
M&A Activity
Warunkowe przyznanie patentu przez Australijski Urząd Patentowy w projekcie ter…
Polish 1.4 KB
2025-05-20 22:12
M&A Activity
Warunkowe przyznanie patentu przez Australijski Urząd Patentowy w projekcie ter…
Polish 1.3 KB
2025-05-20 15:45
Remuneration Information
Sprawozdanie RN o wynagrodzeniach
Polish 1.2 MB
2025-05-20 15:45
Post-Annual General Meeting Information
Podjęte Uchwały
Polish 184.3 KB
2025-05-20 15:45
Post-Annual General Meeting Information
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie PolTREG S.A. w dniu 2…
Polish 729 bytes

Automate Your Workflow. Get a real-time feed of all Poltreg S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Poltreg S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy FF
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.